Charles Schwab
MBIO icon

Charles Schwab’s Mustang Bio MBIO Stock Holding History

Charles Schwab’s Portfolio MBIO Stock Details MBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-42
Closed -$15K – 3558
2022
Q3 		$15K Hold
42
– – ﹤0.01% 3493
2022
Q2 		$19K Sell
42
-219
-84% -$121K ﹤0.01% 3523
2022
Q1 		$198K Hold
261
– – ﹤0.01% 3310
2021
Q4 		$326K Buy
261
+23
+10% +$37.1K ﹤0.01% 3268
2021
Q3 		$482K Hold
238
– – ﹤0.01% 3158
2021
Q2 		$594K Buy
238
+81
+52% +$199K ﹤0.01% 3109
2021
Q1 		$391K Hold
157
– – ﹤0.01% 3166
2020
Q4 		$446K Buy
157
+63
+67% +$151K ﹤0.01% 3028
2020
Q3 		$222K Sell
94
-8
-8% -$19.7K ﹤0.01% 3148
2020
Q2 		$243K Buy
102
+8
+9% +$18.7K ﹤0.01% 3130
2020
Q1 		$189K Hold
94
– – ﹤0.01% 3024
2019
Q4 		$288K Hold
94
– – ﹤0.01% 2983
2019
Q3 		$230K Hold
94
– – ﹤0.01% 3023
2019
Q2 		$260K Buy
94
+36
+62% +$103K ﹤0.01% 3049
2019
Q1 		$150K Buy
58
+16
+38% +$45.3K ﹤0.01% 3059
2018
Q4 		$93K Hold
42
– – ﹤0.01% 3095
2018
Q3 		$187K Hold
42
– – ﹤0.01% 3081
2018
Q2 		$216K Buy
+42
New +$265K ﹤0.01% 3053

Other funds holding MBIO

AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Charles Schwab's MBIO Position: Q4 2022 in Review

Charles Schwab sold out of Mustang Bio (MBIO) in Q4 2022, closing a stake of 42 shares — an estimated $15K sold.

Charles Schwab first reported a position in MBIO in Q2 2018 and held it in 18 quarters. The position peaked at $594K in Q2 2021. 60 funds tracked by Wall St. Rank hold MBIO as of Q4 2022.

  • Charles Schwab reported no remaining Mustang Bio position as of Q4 2022 after selling out during the quarter.
  • Charles Schwab sold 42 Mustang Bio shares in Q4 2022, an estimated $15K.
  • Charles Schwab first reported a position in Mustang Bio in Q2 2018 and held it in 18 quarters.
  • Charles Schwab's Mustang Bio position peaked at $594K in Q2 2021.
  • 60 funds tracked by Wall St. Rank held Mustang Bio as of Q4 2022.

Based on Charles Schwab's 13F filing for Q4 2022, filed 13 Feb 2023.